Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO Patient Guides COVID19 1000x250

Medical management of limited-stage Hodgkin lymphoma

High priority

Your appointment may be a high priority if:

  • shutterstock_1679001136
    You are due to undergo curative systemic treatment for limited-stage Hodgkin lymphoma. In these cases, your doctor may decide to change your planned regimen to a less myelosuppressive one. You may also receive prophylactic growth factors to help boost your immune system and reduce the risk of neutropenia. Appointments between scheduled treatments are likely to be conducted via telephone
  • You are due to undergo curative radiotherapy for limited-stage disease
  • You are receiving treatment as part of a clinical trial 

Medical management of advanced Hodgkin lymphoma

High priority

Your appointment may be a high priority if:

  • shutterstock_1243951615
    You are due to undergo curative systemic treatment for advanced Hodgkin lymphoma. In these cases, your doctor may decide to change your planned regimen to a less myelosuppressive one. Appointments between scheduled treatments are likely to be conducted via telephone. If you are being treated with a chemotherapy regimen that includes bleomycin, you doctor may wish you to have a positron emission tomography scan after two cycles of treatment; if the scan shows that your cancer has responded well to treatment, your regimen may then be adjusted to remove the bleomycin. This means that you can then safely receive prophylactic growth factors to help boost your immune system and reduce the risk of neutropenia
  • You are receiving treatment as part of a clinical trial 

Medical management of relapsed Hodgkin lymphoma

High priority

Your appointment may be a high priority if:

  • shutterstock_1751233217
    You are scheduled to receive high-dose chemotherapy with autologous stem cell support for relapsed Hodgkin lymphoma

Medium priority

Your appointment may be a medium priority if:

  • shutterstock_1126469843
    You are scheduled to undergo maintenance therapy with brentuximab vedotin
  • You are scheduled to receive palliative radiotherapy
  • You are scheduled to receive palliative systemic therapy

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.